Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Resverlogix Corp. (T:RVX)

Business Focus: Bio Therapeutic Drugs

INK Edge Outlook

Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for RVX within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 16, 2019 08:30 ET
Resverlogix Provides Update on BETonMACE Phase 3 Trial
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today that, following the completion of final patient safety visits (as reported by the Company on July 8, 2019), the resolution of all outstanding queries is expected within a...
Read full article
Aug 22, 2019 17:24 ET
Resverlogix Announces Annual and Special Meeting of Shareholders
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today that its Annual and Special Meeting of Shareholders (the “Meeting”) is to be held Thursday, October 31, 2019 at Mount Royal University, Roderick Mah Centre for Continuous...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.66
--
--
Price to Sales - TTM
--
15.50
12.58
Price to Book - most recent quarter
--
4.06
2.74
Price to Cash Flow per share - TTM
--
--
12.18
Price to Free Cash Flow per share - TTM
--
--
18.59
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Aug 31, 2019480,3539,064
Aug 15, 2019471,289-59,901
Jul 31, 2019531,190-23,011
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Fabry disease, other orphan diseases, and peripheral artery disease. Apabetalone is being studied in a Phase III trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $RVX.CA

  • No tweets found

StockTwits